CompletedNCT01364662
SPN-810 Added for Impulsive Aggression in Children With ADHD
About this title
A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
Read the official source — NCT01364662This study evaluated the safety and effectiveness of SPN-810 for people with ADHD.
Medication studyAges 6–12United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SPN-810 for people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
- Listed locations
- Dothan and 26 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJune 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 121
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT01364662
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
Get this study by email
Recruitment & locations
CompletedDothan · Los Angeles · Santa Ana
24 more locations
- Washington D.C.
- Bradenton
- Gainesville
- Hialeah
- Jacksonville
- Maitland
- North Miami
- Orlando
- Tampa
- Atlanta
- Libertyville
- Indianapolis
- Terre Haute
- Owensboro
- Toms River
- Stony Brook
- Cleveland
- Columbus
- Philadelphia
- Pittsburgh
- Charleston
- Memphis
- Bellevue
- Bothell
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SPN-810 for people with ADHD.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SPN-810 and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
